Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. The mutagenic properties of Luxabendazole were investigated in the in vitro Ames Salmonella and E.coli tests. The product was tested at concentrations of 0.5, 5, 50, 500, 1250 and 2500 jig/ plate in the TA1535, TA1538, TA98 and TA100 strains of Salmonella typhimurium, and 03, 5, 50 and 500 ug/plate in the WP2, WP2 uvrA~ and its pKM 101-containing derivative CM891 (WP2 uvrA~ pKMlOl) strains of Escherichia coli, with and without S9 microsomal activation (postmitochondrial liver fraction from Wistar rats pretreated with Aroclor®). Positive and negative controls were included in each experiment From the present study it can be concluded that Luxabendazole, over a dose range of 03-2500 (ig/plate, is unlikely to present a mutagenic hazard, as demonstrated by the Ames test.
Introduction
Luxabendazole (HOE 216 V) is methyl 5-(4-fluorphenylsulfonyloxy)benzimidazole-2 carbamate, a new broad spectrum anthelmintic drug for oral administration synthesised in the research laboratories of Hoechst AG (Frankfurt, Germany) . Luxabendazole, with a molecular weight of 365.34, is a slightly yellowish, crystalline powder with a melting point of 236°C. It is practically insoluble in water and common solvents, but dissolves well in dimethyl formamide (DMF), dimethyl sulfoxide (DMSO) and hot acetic acid (Kassai et al., 1988) .
The drug has proved to be highly effective against adult and immature stages of the major gastrointestinal nematodes {Haemonchus spp., Osfertagia spp., Trichuris spp., Trichostrongylus spp. and Nematodirus spp.) , trematodes (Fasciola hepatica, Dicrocoelium dendriticum) and lung cestodes {Moni-ezia spp.), (Corba et al., 1987; Corba et al, 1989; Kassai et al., 1988; Criado-Fornelio et al., 1990) . Chemotherapy of these infections usually involves compounds with considerable host toxicity, but the low solubility of Luxabendazole compared with the potent benzimidazole compounds could account for this low toxicity because insufficient drug is absorbed to have a toxic effect. However, the main toxic effect of the benzimidazole compounds involves their teratogenic effect. This effect varies with the structure of the benzimidazole and there is species variation in susceptibility (Delatour and Parish, 1986) . The efficacy of a single dose of Luxabendazole (Fluxacur®, Luxacur®) of 10 mg/kg (5% suspension) is 97-100% effective against immature and adult gastrointestinal nematodes in sheep (Abbot, 1987) . In general, the benzimidazole anthelmintics have high therapeutic indices, and during evaluation of the less-soluble compounds, e.g. Luxabendazole, lethal doses could not be established. The maximum tolerated dose of this product in rats is > 10.000 mg/kg body weight (b.w.), and in dogs >320 mg/kg b.w. (Corba et al., 1987) .
Limited information is available on the pharmacological and potential toxic activity of Luxabendazole. However, while use of this benzimidazole carbamate is considered to cause minimal toxicity, the genotoxic potential of Luxabendazole has not been thoroughly established. Such studies are important for any drug to be used on food-producing animals. The tests used in the present study to provide on the genotoxicity of Luxabendazole were: (i) Ames Salmonella typhimurium histidine locus reversion test, conducted with four strains (TA1535, TA1538, TA98 and TA100), in both the presence and absence of rat liver S9 mix and (ii) Escherichia coli tryptophan locus reversion test conducted with three strains (WP2 and its derivatives WP2 uvrAr and WP2 uvrA~ pKMlOl) in both the presence and absence of rat liver S9 mix. This system has been shown to be comparable with the Ames Salmonella strains in its ability to detect mutagens and carcinogens (Bridges et al., 1981) . We carried out all the experiments using the plate protocol.
Material and methods

Chemicals
Luxabendazole
[Methyl-5-(4-fluorophenylsulfonyloxy)benzimidazole-2-carbamate] (purity >99%) was kindly supplied by Dr DUwel of Hoechst Laboratories (Frankfurt, Germany). The molecular structure of Luxabendazole is given in Figure 1 . Stock solutions of the compound were freshly prepared in dimethyl sulfoxide (DMSO). In the E.coli test the final concentration of DMSO did not exceed 20%.
Positive control chemicals were sodium azide, 2-nitroftuorene, 2-aminofluorene obtained from Merck (Darmstadt, Germany), and 2-aminoanthracene and 1-methyl, 3-nitro, 1 '-nitrosoguanidine supplied by Sigma Chemical Co. (St Louis, MO, USA).
NADP and r>Glucose-6P were obtained from Boehringer Mannheim G.m.b.H. (Mannheim, Germany). Dimethyl sulfoxide (DMSO), (+)-Biotin, LHistidine mono hydrate and Ampicillin trihydrate were from Merck (Darmstadt, Germany). Aroclor 1254 was purchased from IFA-CREDO (Madrid, Spain). Media for cell culture were obtained from Oxoid Ltd (Basingstoke, UK). All other reagents were of analytical quality.
Bacterial strains
Ames tester strains as well as E.coli strains were used for the detection of genotoxicity of Luxabendazole.
Histidine-requiring S.typhimurium strains TA1535, TA1538, TA98 and TA100 were kindly provided by Prof. Bruce N.Ames (Department of Biochemistry, University of California, Berkeley, CA, USA). Their genotypes have been described previously by Maron and Ames (1983) . The relevant 
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genetic characteristics of the strains used are described in Table 1 . Frozen permanent copies of the strains were maintained as frozen stock in a liquid N 2 refrigerator. Cultures of the tester strains were grown for 10-12 h at 37°C 
trpE65, AuvrA155, Mai B", pKMlOl "All mutations are on the bacterial chromosome. Deletion through the uvr region blocks excision repair of mutational damage. The rfa mutation enhances cell permeability. The pKMlOl plasmid codes for a constitutive error-prone repair system. The his mutation confer auxotrophy for L-histidine. The tryp mutation confer auxotrophy for tryptophan.
with shaking at 100 r.p.m. in Oxoid Nutrient Broth No. 2 to the stationary phase (1-2X10 9 cells/ml) then divided into aliquot parts and used in all the mutagenesis assays. All bacterial strains were routinely screened on the basis of associated genetic characteristics, being cultured from a single colony from the master plates, and positive mutagenesis controls using standard mutagens (Maron and Ames, 1983) were included in each experiment.
Tryptophan-requiring E.coli strain WP2 and its derivatives WP2 uvrA" and WP2 uvrA-pKMlOl, were kindly provided by Prof. M.H.L.Green (MRC Cell Mutation Unit, University of Sussex, UK). Relevant genetic information is given in Table 1 . Strain WP2 is a repair-proficient parent strain (UV resistant), WP2 uvrA~ lacks excision repair, so that it is more readily mutated by agents such as UV which cause bulky non-coding lesions in DNA, and strain CM891 contains the plasmid pKMlOl. Cultures are streaked out on nutrient agar plates, incubated at 37°C overnight, and stored at 4°C for up to a month before re-streaking. For long-term storage, after a streaked plate is incubated overnight, a single colony is touched with a sterile inoculating needle and a small inoculum is stabbed into a slab agar tube. The tube is carefully sealed and stored at room temperature. Cultures can survive for several years stored in this way. To prepare a stock for testing, portions of a single colony were inoculated in several universals containing 10 ml of Oxoid Nutrient Broth No. 2 supplemented with 10% tryptophan (10 |ig/ml) and incubated at 37°C overnight with shaking until the cells reached a density of 2X lfZ/ml. These bacterial inoculums were utilized in the mutagenicity assay which was carried out essentially in accordance with the test described by Green (1984) and Hubbard el al. (1984) . •Values are the mean of revertants for three plates. SD: standard deviations. MI: mutation index. SR: spontaneous revertants. Solvent control, DMSO 100 |xl. c Sodium azide at 1.5 |ig per plate for TA1535 and TA100; 2,4-nitrofluorene at 2 |ig per plate for TA1538 and TA98.
-Aminoacthracene at 4.0 (lg per plate for TA1535, and 2-aminofluorene at 10 ng per plate for TA98, TA100 and TAI538.
Mutagenic evaluation of Luxabendazole
Metabolic activation
The supernatant of the post-mitochondrial liver fraction (S9) from SpragueDawley male rats of weight -200 g, induced with Aroclor 1254 (a polychlorinated biphenyl, PCB, mixture), was used to provide metabolism of the compounds. The rat liver S9 fraction was prepared as described by Maron and Ames (1983) and stored in a liquid N 2 refrigerator. Aroclor 1254 was diluted in com oil to a concentration of 200 mg/ml and a single i.p. injection of 500 mg/kg was administered to each rat 5 days before the homogenate preparation date. Protein concentration of the S9 fraction was determined by the Coomasie blue method (Bradford, 1976) . For a standard assay the S9-mix consists of 0.1 ml of S9 fraction (30 mg/ml), 8 nmol MgCl 2 , 33 nmol KC1, 5 nmol G-6P, 4 |imol NADP and 100 |imol sodium phosphate, pH 7.4/ml of mix.
Mutation assays
Luxabendazole was previously tested for toxicity in order to decide the subtoxic concentrations that would be assayed in the mutagenicity test. Mutagenicity assays were performed according to the plate incorporation method described by Maron and Ames (1983) for S.typhimurium and by Green (1984) for E.coli. Experiments were in the absence of mammalian metabolic activation (S9-mix) except where indicated. In brief, in the Salmonella assay, to 2 ml of top agar supplemented with 0.2 ml of a 0.5 mM histidine/biotine solution were added 100 |il of the appropriate Luxabendazole solution, 100 |il of an exponential bacterial culture of the tester strain and, when the experiment was performed using a metabolic activation system. 500 nl of S9-mix. After shaking, the mixture was spread onto a minimal glucose agar plate. Control plates were included in all experiments for determination of spontaneous reversion and mutants, and contained 100 (xl of DMSO. Plates were placed in a 37°C incubator in the dark for at least 48 h, after which revertants were counted. Each experiment was performed in triplicate, both with and without S9 activation, for each tester strain and chemical concentration, and results were expressed as the average number of revertants per plate. Each assay was repeated on at least two separate occasions with a wide range of chemical concentrations. For each experiment, spontaneous reversion and mutation in response to DMSO and positive response to the standard mutagen controls were included to ensure the validity of the test. The positive controls used per plate in the Salmonella assays were 1.5 |ig sodium azide (TA1535 and TA100) and 2 |ig 2,4-nitrofluorene (TA1538 and TA98) when the assays were performed in the absence of S9-mix, and 10 u.g of 2-aminofluorene (TA98, TA100, TA1538) and 4 ng of 2-aminoanthracene (TA1535) when assays were performed in the presence of S9-mix. In the E.coli tests the positive controls used were 10 (ig/plate of 1-methyl, 3-nitro, 1 '-nitrosoguanidine (MNNG) in the absence of S9-mix, and 0.1 |ig/plate of 2-aminofluorene in the presence of mammalian metabolic activation for all strains, respectively.
Mutagenic response
The mutagenic responses were expressed as the number of His + revertants induced per selective plate. Controls without mutagen were included in all experiments for determination of spontaneous counts. Data are expressed as •Values are the mean revertants for three plates. SD: standard deviation. MI: mutation index. SR: spontaneous revertants. ''Solvent control, 100 Hi DMSO: H2O (20:80, v/v) . C l-Methyl, 3-nitro, l'-nitrosoguanidine at 10 \ig per plate.
•^-Aminofluorene at 0.1 ng per plate. mean ± SD, and the mutation index was obtained as: MI = x, / XQ where x, is the mean of revertants colonies (mutants) at each dose assayed, and XQ is the mean of revertants at negative control. A test compound was considered mutagenic if the number of the His + revertant colonies was at least twice the value of the corresponding solvent control (mutation index >2), over at least three dose levels, and a reproducible dose-response curve could be demonstrated.
Results
The anthelmintic Luxabendazole was tested for mutagenicity 'in vitro' with the Ames test using the S.typhimurium His", and the E.coli Tryp" test, both in the absence and in the presence of an exogenous metabolizing system (S9-mix).
In conformity with the current standards of the O.E.C.D. and the E.U. for the analysis of pure chemicals, the maximum concentration to be tested is fixed at 5 mg/plate, as long as this is feasible due to good solubility of the sample, without the solution being saturated, cloudy, or otherwise unsuitable. The solution of LBZ in DMSO which must be prepared in order to attain a concentration of 5 mg/plate is a virtually saturated solution which precipitates as soon as it comes in contact with the Top-agar of the culture medium (it includes water). Precipitation of the chemical gives rise to the appearance of small white granules of LBZ which makes it difficult to discriminate between granules of LBZ and the few colonies of Salmonella which are able to grow under these test conditions. Thus, this concentration is toxic and unsuitable for testing. When the test is performed with 2500 n.g LBZ/plate, the same problem occurs as was noted with the higher concentration initially tried, although less strikingly. Despite this, the test was performed and a count made of colonies grown, though keeping in mind possible reading errors. Under these test conditions a slightly lower mutation rate than that observed in controls became evident, especially when the tests were performed without S9-mix fraction. This might indicate a somewhat toxic character for the chemical at this concentration. In spite of this, the data obtained are included in Table II. From the analyses carried out in the current work it is possible to conclude that as evidenced by a sparse background lawn, and relatively small colonies, Luxabendazole was toxic to strains tested at 5000 u.g/plate, and subtoxic at 2500 fig/plate doses. This cytotoxic effect was not observed when Luxabendazole was assayed at lower concentrations (>1250 u.g/plate). Therefore, the product was tested up to 2500 fig/plate. These results indicated low toxicity of Luxabendazole in these bacterial assays.
With respect to the studies performed with E.coli, since the concentration of DMSO, used as the solvent for the sample, which is added to the cultures cannot exceed 20%, the greatest concentration of Luxabendazole which may be tested under these conditions is 500 (ig/plate.
For each experiment, spontaneous reversion and mutation in response to DMSO and a positive response to the reference mutagen were included to ensure the validity of the test. The number of spontaneous revertants observed for each strain was within the range previously established in our laboratory. Similarly, the response of the positive controls was as expected. The results of the test are presented in Tables II and HI . No evidence of mutagenic activity was observed in any of the experiments performed, either in the absence or in the presence of rat liver S9 metabolic activation for all the strains tested. According to the mutation index, Luxabendazole did not show mutagenic activity. The maximun mutation index obtained was 1.8 for TA1535 (Table II) and 1.4 for WP2 and WP2 uvrA (  Table III) .
Discussion
Because of the poor solubility of Luxabendazole in DMSO at the highest concentration studied (5 mg/plate) and in particular the tendency of the sample to precipitate as soon as it comes into contact with the Top-agar (it contains water), we feel that only the results obtained from concentrations of 1250 (ig/plate and below are valid. For 2500 ^g/plate, even though the results have been included in the appropriate table (Table II) , the data are not wholly reliable, as colonies might be partially masked by precipitated granules of Luxabendazole. In each test the negative and positive controls gave an acceptable number of revertants (Maron and Ames, 1983; Hubbard et al., 1984) . Positive control agents caused a significant increase in the number of revertants compared with the negative control, thereby validating the methodology. The sensitivity of the test in detecting the non-mutagenic effect of Luxabendazole is apparently the same in conditions closer to those of mammalian metabolism.
The results of the standard plate incorporation assays suggested that Luxabendazole was of low toxicity and that it was not mutagenic. Similar results were obtained in both the absence and the presence of S9 mix. The data obtained from this study indicate that LBZ is non mutagenic under these test conditions. However, it is important that these negative results be followed by a series of comprehensive in vitro investigations to assess further the non-mutagenic potential of LBZ. The mutagenic or non-mutagenic potential of an agent cannot be reliably determined by any single genotoxic test procedure (de Serres and Matsushima, 1987) . In the present study, however, Luxabendazole gives uniformly negative results in the assays performed, and presented a reassuring safety profile. Furthermore, the use of different assay methods allowed us to obtain more information about the behaviour of LBZ.
